Get the Stockscreener App
0.635
3.42%
0.021
Promis Neurosciences Inc stock is traded at $0.635, with a volume of 109.16K.
It is up +3.42% in the last 24 hours and down -13.13% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.614
Open:
$0.6141
24h Volume:
109.16K
Relative Volume:
2.68
Market Cap:
$18.78M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-3.1814
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
+14.93%
1M Performance:
-13.13%
6M Performance:
-39.23%
1Y Performance:
-65.86%
1-Day Range:
$0.577
$0.64
1-Week Range:
$0.5111
$0.6489
52-Week Range:
$0.5111
$2.37
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.635 | 18.78M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Stock (PMN) Latest News
Parkinson’s vaccine selectively targets pathogenic αSyn - BioWorld MedTech
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World
ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks
ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq
ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Form 424B5 ProMIS Neurosciences - StreetInsider
ProMIS Neurosciences Inc. SEC 10-K Report - TradingView
ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia
New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı
ProMIS to present neurodegenerative disease research - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance
ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia
ProMIS to present vaccine data at neurology meeting - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq
ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire
PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire
ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World
ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com India
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
ProMIS Neurosciences begins Alzheimer’s trial dosing By Investing.com - Investing.com South Africa
ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian
Multiple System Atrophy Clinical Trials and Pipeline 2025: EMA, - openPR
ProMIS Neurosciences Announces COO Position Termination - TipRanks
ProMIS Neurosciences stock hits 52-week low at $0.85 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences dismisses COO position - MSN
ProMIS Neurosciences announces COO departure - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.85 - Investing.com
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Promis Neurosciences Inc Stock (PMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
| Kirwin Patrick D. | Director |
Aug 14 '24 |
Buy |
1.25 |
10,000 |
12,492 |
62,983 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):